Axsome Therapeutics saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 66 to 82.
IBD's unique rating measures price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners tend to have an RS Rating north of 80 as they begin their biggest runs.
Looking For The Best Stocks To Buy And Watch? Start Here
Axsome Therapeutics is now considered extended and out of buy range after clearing a 97.00 buy point in a second-stage cup with handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Axsome Therapeutics posted 0% EPS growth in the latest quarterly report. Revenue rose 81%.
The company holds the No. 77 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
